FLT3 as a Marker of Minimal Residual Disease: Time to Re-Think?

American Journal of Hematology - United States
doi 10.1002/ajh.24667
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology
Hematology
2018English

Minimal Residual Disease

Leukemia Supplements
2012English

Minimal Residual Disease

Bone Marrow Transplantation
TransplantationHematology
2001English

Re-Emergence of Chronic Obstructive Pulmonary Disease: It Is Time to Think COPDifferently

Singapore Medical Journal
Medicine
2013English

Concomitant Monitoring ofWT1andFLT3-ITDexpression inFLT3-ITDacute Myeloid Leukemia Patients: Which Should We Trust as a Minimal Residual Disease Marker?

American Journal of Hematology
Hematology
2017English

Workshop on Minimal Residual Disease

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2001English

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Clinical Cancer Research
Cancer ResearchOncology
2015English

On the Way to Specifically Targeting Minimal Residual Disease?

Breast Cancer Research
Cancer ResearchOncology
2008English

Old Cavity, New Cancer – Is It Time to Re-Think?

JRSM Short Reports
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy